Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 1011.

https://doi.org/10.1182/blood-2024-211454

Published: 2024

Journal Articles

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Hua-Jay J Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2024) 144 (Supplement 1): 336.

https://doi.org/10.1182/blood-2024-203382

Published: 2024

Journal Articles

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Blood (2024) 144 (Supplement 1): 6451.

https://doi.org/10.1182/blood-2024-194844

Published: 2024

Journal Articles

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

Juan Pablo Alderuccio, Jahanzaib Khwaja, Sunwoo Han, Paola Ghione, Imran A. Nizamuddin, Aditi Saha, Ning Dong, Yucai Wang, Hua-Jay J Cherng, Seda S. Tolu, Nina Wagner-Johnston, Adam J. Olszewski, Natalie Grover, Jean L. Koff, Amrita Desai, Praveen Ramakrishnan Geethakumari, Tamara K Moyo, Jose Sandoval-Sus, Narendranath Epperla, Danielle S Wallace, Manali Kamdar, Alexey Danilov, Han W. Tun, Javier Munoz, Mayur S. Narkhede, Joanna M. Rhodes, Anca Prica, Andrea Kuhnl, Adrian Maraj, Jessica Okosun, Jeffery Smith, Wendy Osborne, Victoria Calvert, Dima el-Sharkawi, Ammar Hilali, Graham P. Collins, Kim Linton, Nagah Elmusharaf, Anna Santarsieri, Farheen Karim, Thomas Ollila, Sarah Monick, Iris Margalit Trutzer, Nilanjan Ghosh, Jones Can, Amy Ayers, Jacopo Calabrese De Feo, John Sharp, Rachel Treitman, Avyakta Kallam, Izel Okcu, Vismay Deshani, Firas Baidoun, Chathuri Abeyakoon, William Hann, Aisling Barrett, Brad Kahl, Julio C. Chavez, Kate Cwynarski

Blood (2024) 144 (Supplement 1): 571.

https://doi.org/10.1182/blood-2024-199781

Published: 2024

Journal Articles

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Blood (2024) 144 (Supplement 1): 652.

https://doi.org/10.1182/blood-2024-202153

Published: 2024

Journal Articles

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

Hua-Jay J Cherng, Rebecca Scalabrino, Patrick Gould, Alexander Sanjurjo, Brian Cuzzo, Saagar Jain, Hong Y Ma, Maegan Ford, Evelyn H. Orlando, Dorine De Jong, Manuela A Orjuela, Andrew H. Lipsky, Seda S. Tolu, Barbara Pro, Jennifer E. Amengual, Kathleen M Capaccione

Blood (2024) 144 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2024-194265

Published: 2024

Journal Articles

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Jennifer E. Amengual, Aung M. Tun, Ted B. Piorczynski, Yun Kyoung Tiger, Victor Yazbeck, Hua-Jay J Cherng, Seda S. Tolu, Barbara Pro, Diane Durecki, Jan Beumer, Neil Kelleher, Naomi Sender, Sarah Sta Ana, Anxhela Kalia, Beatriz Raposo Corradini, Yu Shyr, Patricia LoRusso, Lorraine Pelosof, Richard Piekarz

Blood (2024) 144 (Supplement 1): 3112.

https://doi.org/10.1182/blood-2024-199650

Published: 2024

Journal Articles

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Kishan A Bhatt, David M. DeStephano, Rhea K Khurana, Claire Sathe, Seda S. Tolu, Hua-Jay J. Cherng, Jennifer E. Amengual, Barbara Pro, Dawn L Hershman, Justine M. Kahn, Melissa P Beauchemin

Blood (2024) 144 (Supplement 1): 5042.

https://doi.org/10.1182/blood-2024-210508

Published: 2024

Journal Articles

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

Blood (2024) 144 (Supplement 1): 1739.

https://doi.org/10.1182/blood-2024-192979

Published: 2024

Journal Articles

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

Blood (2023) 142 (Supplement 1): 990.

https://doi.org/10.1182/blood-2023-177823

Published: 2023

Journal Articles

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Seda S. Tolu, Ted B. Piorczynski, Manuel Pazos, II, Brian Estrella, Wenxuan Huang, Yun Kyoung Ryu, Hua-Jay J. Cherng, Barbara Pro, Jennifer E. Amengual

Blood (2023) 142 (Supplement 1): 6118.

https://doi.org/10.1182/blood-2023-180875

Published: 2023

Journal Articles

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Hua-Jay J. Cherng, Xiaojing Yang, Ryan Yancey, Christian A Gordillo, Ted B. Piorczynski, Hei T. Chan, Kenneth N. Ofori, Govind Bhagat, Andrea Califano, Barbara Pro, Keith Booher, Jennifer E. Amengual, Ran Reshef, Abu A. I. Sina

Blood (2023) 142 (Supplement 1): 4371.

https://doi.org/10.1182/blood-2023-178376

Published: 2023

Journal Articles

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Jan Boegeholz, Stefan K. Alig, Brian Sworder, Joseph Schroers-Martin, Charles Macaulay, Alexander F.M. Craig, Ulrich Duehrsen, Andreas Hüttmann, Jason Westin, Hua-Jay J. Cherng, David B. Miklos, Matthew J Frank, Maximilian Diehn, David M. Kurtz, Ash A. Alizadeh

Blood (2022) 140 (Supplement 1): 8609–8610.

https://doi.org/10.1182/blood-2022-170087

Published: 2022

Journal Articles

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Blood (2022) 140 (5): 504–515.

https://doi.org/10.1182/blood.2022015601

Published: 2022

Includes: Supplemental data

Journal Articles

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Hua-Jay J. Cherng, Raamis Khwaja, Rashmi Kanagal-Shamanna, Jan A. Burger, Philip A. Thompson, Alessandra Ferrajoli, Zeev E. Estrov, Koji Sasaki, Deepa Sampath, Guilin Tang, Xuemei Wang, Hagop Kantarjian, Michael J. Keating, William G. Wierda, Nitin Jain

Blood (2021) 138 (Supplement 1): 394.

https://doi.org/10.1182/blood-2021-146432

Published: 2021

Journal Articles

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Blood (2021) 138 (Supplement 1): 38.

https://doi.org/10.1182/blood-2021-148314

Published: 2021

Journal Articles

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Hua-Jay J Cherng, MD, Raphael E Steiner, MD, Luis Fayad, Paolo Strati, MD, Ranjit Nair, MD, F. B. B. Hagemeister, MD, Loretta J. Nastoupil, MD, Hun Ju Lee, MD, Sattva S. Neelapu, MD, Christopher Flowers, MDMS, Felipe Samaniego, MD, Maria Alma Rodriguez, MD, Lei Feng, MS, Hubert Chuang, MDPhD, Jason R. Westin, MD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134203

Published: 2020

Journal Articles

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Hua-Jay J Cherng, MD, Nadya Jammal, PharmD, Shilpa Paul, PharmD, Xuemei Wang, MS, Koji Sasaki, MD, Philip A. Thompson, MB, MS, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Susan M. O'Brien, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD, Nitin Jain, MD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-135938

Published: 2020

Journal Articles

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC -Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Hua-Jay J. Cherng, MD, Rachel Lynn Sargent, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD, Anthony R. Mato, MD, April Schrank-Hacker, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2017) 130 (Supplement 1): 4136.

https://doi.org/10.1182/blood.V130.Suppl_1.4136.4136

Published: 2017

NARROW

Combined Pirtobrutinib, Venetoclax, and Obinutuzumab As First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Combination JAK Inhibition and Immune Checkpoint Blockade for the Treatment of 9p Amplified Lymphomas

TP53 -Altered Aggressive Large B-Cell Lymphoma (LBCL) Outcomes By Treatment Modality: A Multicenter Cohort from 14 U.S. Centers

Prognostication and Treatment-Related Outcomes in Secondary Central Nervous System Involvement of Large B-Cell Lymphoma (SCNSL): Evidence from a Large International Cohort

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Diagnostic Utility of the 18 f-FDG PET/CT Scan in Solid Organ Transplant Patients with EBV Reactivation at Risk for Post-Transplant Lymphoproliferative Disorder

Etctn P10500: Phase 1 Study of Tazemetostat Plus Belinostat for the Treatment of Relapsed or Refractory Lymphoma

Association between Food Insecurity, Financial Toxicity, and Healthcare Utilization in Patients with Lymphoma

Safety and Efficacy in Patients with Advanced Lymphomas from a Global Phase 1a/1b, First-in-Human Study of CS5001, a Novel Anti-ROR1 ADC

The Effect of Preemptive Rituximab Treatment in Patients with EBV Viremia after Solid Organ Transplantation on the Development of Post-Transplant Lymphoproliferative Disorder

JAK1/2 Inhibition Modulates Key Markers of Lymphomagenesis in 9p24.1 Amplified Lymphoma, Priming for Enhanced Antigenicity

Methylated Whole Genome Cell-Free DNA Sequencing before Chimeric Antigen Receptor T-Cell Therapy for Large B-Cell Lymphoma Predicts Treatment Outcomes

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC -Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only